Obesity and Consequences
The prevalence of overweight and obesity has reached epidemic proportion, with the recent figures from the World Health Organization indicating that in 2016 39% of adults aged ≥18 years (39% of men and 40% of women) were overweight and 13% (11% of men and 15% of women) obese. The World Health Organization states that raised body mass index (BMI) is a major risk factor for noncommunicable diseases such as cardiovascular diseases (mainly heart disease and stroke), which were the leading causes of death in 2012, diabetes mellitus, musculoskeletal disorders, and some cancers. 1 The Framingham Heart Study data have indicated that overweight and obesity are associated with significantly decreased life expectancy. 2 Nevertheless, and against these strong evidences, the relationship between BMI and mortality has been challenged by several studies, indicating a survival advantages for those who are overweight and class I obese. 3 However, the determinants of these observations are poorly understood and continue to be debated because BMI may not be the ideal index of adiposity and fat distribution and fitness and disease prevention may obscure the link between BMI and mortality. 4 Overweight or obesity is not always accompanied by traditional risk factors. In fact, a systematic review and metaanalysis revealed that about 35% of obese individuals are metabolically healthy. 5 A large study indicated that general or abdominal obesity, in the absence of metabolic risk factors, was not associated with mortality risk compared with lean individuals. 6 These data differed from those of the Health Improvement Network, which comprised a cohort of 3.5 million individuals revealing that during a mean follow-up of 5.4 years, obese individuals with no metabolic abnormalities had a higher risk of coronary heart disease, cerebrovascular disease, and heart failure compared with healthy normalweight individuals. 7 This indicates that even in the absence of metabolic abnormalities, overweight and obesity are not innocuous, perhaps because the traditional cardiovascular risk factors are either not present early or remain undetected using routine clinical assessment. This raises the concept that early or subclinical organ damage assessments may be better at identifying subjects who are more likely to progress to develop cardiovascular disease. There is evidence that an important factor driving at least some of the obesity-associated end-organ damage is overactivity of the sympathetic nervous system (SNS), an observation that suggests that targeting SNS in obesity may help reduce the cardiovascular risk associated with obesity. In this review, we highlight the current knowledge of the potential role of SNS function in obesity-induced organ damage and examine whether interventions aimed at reducing cardiovascular risk in obesity may be mediated via alterations in SNS activity. While not discounting the important and prolific preclinical data on this subject, our review is primarily focused on recent observations from human trials.
The State of Sympathetic Activity in Human Obesity
Generalized sympathetic activation is a hallmark of many important clinical conditions including hypertension, heart failure, and chronic kidney disease and, importantly, has been linked to poor prognosis. 8 Considering experimental work, it was initially proposed that sympathetic tone was low in obesity. 9 Assessment of sympathetic activity in human obesity originally produced conflicting results, possibly due to methodological issues. Although plasma and urinary norepinephrine sampling is relatively easy to perform, these measures, at best, provide only a global marker of sympathetic activity and have led to conflicting results. 10 More robust techniques, including whole body and regional norepinephrine spillover to plasma, microneurography, and pharmacological methods, have shown more consistent results. Excess adiposity has in general been associated with elevated sympathetic activity to the kidneys and to the skeletal muscle but not to the heart.
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Sympathetic activation is, however, absent in certain types of obesity including that seen in Pima Indians. 12 The sympathetic activation present in those who are overweight occurs even in the absence of any clinically significant metabolic or cardiovascular abnormalities, suggesting that sympathetic overdrive is inherent to the adiposity and occurs early before any manifestation of vascular or metabolic abnormalities. 13 It is important to note that sympathetic tone in the presence of excess adiposity seems to be influenced by many factors with, for instance, a more visceral fat deposition, the presence of sleep apnea, elevated blood pressure (BP), insulin resistance, dyslipidemia, and the presence of polycystic ovary syndrome, all of which seems to enhance the already compromised sympathetic drive to the skeletal muscle.
14 How obesity may lead to an increase in sympathetic activity has been investigated in many experimental and clinical studies. [14] [15] [16] Aberrant sympathetic tone seen in the presence of excess weight, in concert with other mechanisms, is likely to affect metabolic dysfunction, including insulin resistance and diabetes mellitus development, as well as organ dysfunction even at an early stage ( Figure 1 ). The impact of obesity on early organ dysfunction and the role of the SNS activity will be discussed below.
Evidence for Obesity-Associated Subclinical Target Organ Damage Sympathetic Activity and BP Rise in Obesity
Several studies have demonstrated a clear association of BP increase with weight gain. It has been shown that obese subjects have a 3.5-fold increased likelihood of having hypertension and that 60% of hypertension is attributable to increase in adipose stores. Currently, the prevalence of hypertension is estimated to be between 36% and 47% among the obese population compared with 20% in normal-weight individuals. 17 The prevalence of pre-hypertension (BP 120-139/80-89 mm Hg) is, however, even higher, with a study in Southern China indicating that pre-hypertension was present in 42% of overweight and 42% of obese males and 32% and 31% of overweight and obese females, respectively. 18 A highly reproducible and early rise in BP is observed with excess weight gain induced by a high-fat diet in rabbits. 19 Although the time course between weight gain and BP elevation is more difficult to establish in the clinical setting, a similar pattern seems to occur in humans. A 5-year longitudinal study in young, nonobese, normotensive men demonstrated that increase in plasma norepinephrine levels preceded subsequent weight gain and BP elevation. 20 In addition, Gentile et al 21 demonstrated that in nonobese male subjects, experimental overfeeding for 4 weeks resulted in a modest 5 kg gain, which was associated with a rise in muscle sympathetic nerve activity (MSNA) of 15% to 20% ( Figure 2 ) and systolic BP by 3 mm Hg. Likewise, in a more recent study, the exposure of lean, healthy individuals to an 8-week overfeeding challenge induced modest weight gain of 3.7 kg and resulted in significantly elevated 24-hour ambulatory BP by 4 mm Hg. Interestingly, this pressure response was selectively associated with visceral fat expansion. 22 Although these changes may be seen as modest, it is prognostically significant, as individuals with pre-hypertension have a 2-to 3-fold higher risk of developing hypertension than those who are normotensive. 23 The mechanisms responsible for generating obesity and obesity-related hypertension are complex and sometimes interdependent. The main players may include genetic and environmental factors, SNS activation, renal and adrenal function, endothelial dysfunction, adipokines, natriuretric peptide deficiency, and the development of insulin resistance. The evidence for involvement of the SNS in the pathogenesis of human obesity-associated hypertension stems from observational studies noting further elevated MSNA in patients with the combination of obesity and hypertension 24 and pharmacological studies, as combined treatment with α-and β-adrenoreceptor antagonists are more effective in lowering BP in obese individuals compared with lean hypertensive patients. 25 Nevertheless, not every obese subject presents with elevated BP. We previously found that normotensive overweight women have normal values of MSNA, while normotensive but overweight males had increased MSNA. 26 This suggests that even if sympathetic overdrive is present, it may not always have an immediate effect on BP. Other mechanisms may be necessary with perhaps visceral fat being a key determinant of BP rise.
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Sympathetic Activity and Renal Function in Obesity
Although the impact of obesity on chronic kidney disease may be modulated by the presence of comorbidities including diabetes mellitus and hypertension, excess weight is now recognized to be a crucial factor.
Kidney impairment in obesity starts with glomerular hyperfiltration, which is observed before the appearance of glomerulomegaly or renal dysfunction, thus it could be considered as an early marker of renal damage. The importance of glomerular hyperfiltration was reinforced by 2 studies; a large prospective study indicated that glomerular hyperfiltration was a strong and independent predictor of cardiovascular events in a multiethnic population of predominantly hypertensive individuals, 27 and another which indicated that glomerular hyperfiltration was a predictor of cardiometabolic risk factor development among children and adolescents. 28 Sympathetic overactivity to the kidneys has been observed in obese individuals, even in the absence of hypertension, 11 and is likely to play a role in the development of cardiovascular and renal diseases. In young adults, those overweight or obese subjects free of metabolic or cardiovascular disorders had elevated creatinine clearance compared with their lean counterparts and the creatinine clearance was directly and positively correlated with MSNA ( Figure 3) . 13 While this observation does not imply causality, the link between increased MSNA and glomerular hyperfiltration early in the pathogenesis of obesity suggests that neurally mediated increases in tubular sodium reabsorption may play a role in obesity-related kidney dysfunction. 29 Hall et al 29 suggested that fat infiltration and abdominal fat accumulation causes tubular compression, thus further increasing sodium reabsorption. The possible role of the SNS activation in the glomerular hyperfiltration is reinforced by a number of studies indicating improved glomerular hyperfiltration after sympathetic inhibition using either chronic baroreflex activation in dogs 30 and a combination of moxonidine and a low-calorie diet in young males 31 ( Figure 4 ).
Sympathetic Activity and Endothelial function in Obesity
Endothelial dysfunction is recognized as an early, yet reversible, precursor of atherosclerosis. Not only is endothelial dysfunction associated with a worse clinical outcome in individuals with atherosclerosis who are also at high cardiovascular risk, but some studies have also shown that it may be an important marker of risk even in those at otherwise low risk. 32 It is well established that overweight or obese healthy adults present with impaired vasodilating properties of the endothelium or endothelial dysfunction suggesting increased risk for cardiovascular disease development. 33 Recently, it was found that endothelial dysfunction was present in metabolically healthy obese individuals, although the extent of impairment was less marked Association between sympathetic activity and end organ damage. Linear regression analysis of the relationship between muscle sympathetic nerve activity (MSNA) and endothelial function as assessed using Pulse Amplitude Tonometry (PAT) ratio (A), creatinine clearance (B), and left ventricular mass index (LVMI; C) in young individuals over a body mass index (BMI) ranging from lean to obese. Data were adjusted for BMI, sex, and blood pressure. 13 Reprinted from Lambert et al. [13] . Copyright © 2010, American Heart Association, Inc.
compared with those with the metabolic syndrome. 34 While the mechanisms linking obesity with endothelial dysfunction have not yet been fully clarified, many factors have been proposed to mediate this process including vascular proinflammatory factors and oxidative stress, increased generation of reactive oxygen species or reduced antioxidant defence, disturbance in the vascular profile of prostanoid release, effects of perivascular adipose tissue, increased production or activity of endothelin-1 and angiotensin II and insulin resistance. 33 The SNS may also directly influence the endothelium. Both α2-adrenoceptors and β-adrenoceptors are expressed on endothelial cells. 35 Given that activation of endothelial adrenergic receptors releases endothelium-derived relaxant factors like nitric oxide and endotheliumderived contracting factors such as endothelin-1, 35 disturbances in SNS activity may affect the balance between relaxant and contracting factors, hence leading to abnormal endothelial function in obesity. In support to this concept, in individuals who are healthy and overweight, endothelial function could be predicted by both BP and MSNA (Figure 3) . 13 Nevertheless, studies have documented diverse effects of sympathetic inhibition on endothelial function possibly due to different methodologies used: acute autonomic blockade in obese hypertensive subjects results in reversal of endothelial dysfunction. 36 Three-month moxonidine treatment in conjunction with a low-calorie diet further improved endothelial function in patients with hypertension and obesity compared with those on a diet alone; however, the patients on moxonidine lost more weight and displayed greater BP reduction, perhaps confounding these improvement. 37 Other long-term studies reported that moxonidine, given alone or in combination with a low-calorie diet had no effect on the endothelial function in older patients with hypertension 38 or in young overweight males 31 ( Figure 4) . Similarly, renal nerve ablation in obese hypertensive patients failed to improve endothelial function at 3-and 6-month post-procedure. 39 While the link between SNS overactivity and endothelial dysfunction is recognized, consistent evidence documenting improvement in endothelial function after interventions to block or reduce SNS is lacking.
Sympathetic Activity and Cardiac Function in Obesity
Obesity, particularly severe obesity (BMI≥40 kg/m 2 ), is associated with changes in cardiac morphology and ventricular function that may contribute to the development of cardiac failure, even in the absence of comorbidities such as coronary artery disease or hypertension and heart failure. Regardless of the severity of obesity or the technique used to assess left ventricular (LV) morphology, elevated LV mass, and LV diastolic dysfunction have consistently been found in obese subjects. 40 Kenchaiah et al 41 , using the Framingham Heart Study cohort, showed a 5% to 7% increase in risk of heart failure for every 1 kg/m 2 increase in BMI based on a 14-year follow-up. While early studies suggested that changes in cardiac structure and ventricular function associated with obesity were attributable to hemodynamic alterations (augmented total blood volume and cardiac output, decreased systemic vascular resistance), a growing body of research indicates that autonomic dysfunction including both sympathetic and parasympathetic aberrations and metabolic alterations associated with obesity may also play a key role in obesity-related changes in cardiac structure and function. 40 Obesity is characterized by enhanced activation of the renin-angiotensin system. Such activation has many implications in relation to cardiac structure and function, in particular is the vasoconstriction effect of angiotensin II, as well as its effects on LV afterload, volume expansion, insulin resistance, and hyperinsulinemia. 40 Activation of the reninangiotensin system may lead to increased SNS activity, further contributing to the development of LV hypertrophy. The impact of high sympathetic drive on cardiac remodeling is evidenced by a number of observations: the LV hypertrophy that occurs in overweight individuals was found to regress more by inhibiting the renin-angiotensin system and SNS neuroendocrine pathways compared with using bendroflumethiazide and amlodipine, which induced comparable BP reduction. 42 A reduction in LV mass after renal denervation is also observed in overweight patients with resistant hypertension, although it is not possible to distinguish how much is caused by BP reduction or related to reduction in sympathetic activity. 43 
Sympathetic Activity and Arterial Stiffness in Obesity
Arterial stiffness is a key manifestation of vascular aging and is characterized by functional and structural changes of the arterial wall and has been associated with incident cardiovascular disease. 44 Beyond the effect of age, arterial stiffness can be accelerated by exposure to poor lifestyle across the lifespan, and thus, may be, at least in part, a modifiable process. As such, obesity has emerged as an important risk factor for the development of arterial stiffness. Data from the Whitehall II study 45 indicated that previous adiposity was associated with aortic stiffening independent of change in adiposity, glycemia, and lipid levels and indicated that the BMI-linked pulse wave velocity (an index of arterial stiffness) increase accounts for 12% of the projected increase in cardiovascular risk associated with obesity. In addition, a study 46 indicated that participants who remained heavy from 8 to 45 years, and who were lean in childhood but gained weight in young adulthood, subsequently had the highest values of carotid stiffness and highest odds of hypertension. In addition to changes in the mechanical stretching of the arterial wall conferring arterial stiffness, there is evidence that genetic characteristics, inflammation, the generation of oxygen-reactive species, endothelial dysfunction, and calcium and phosphate metabolism disorders are playing an important part in the generation of vascular aging. 47 Whether activation of the SNS contributes to increases in arterial stiffness independent of changes in BP remains unclear because arterial stiffening coexists commonly with chronic elevations in both basal sympathetic outflow and high BP in cardiovascular disease states. While in 16 healthy subjects, neither brachial artery distensibility nor carotid artery distensibility were related to MSNA, 48 another study showed evidence that pulse wave velocity was linked to MSNA in 25 healthy adults and that this relationship between MSNA and pulse wave velocity was independent of age, BMI, waist circumference, heart rate, pulse pressure, or BP. 49 More recently, Nardone et al 50 indicated that in young healthy participants, a modest increase in MSNA induced by acute low body negative pressure resulted in increased central and whole-body measures of arterial stiffness, independent of a change in BP or heart rate, suggesting that elevation in the sympathetic tone may affect arterial stiffness. Likewise, Harvey et al 51 demonstrated that multiple aortic hemodynamic parameters are negatively influenced by sympathetic nerve activity to a greater extent in older postmenopausal women than in young premenopausal women. However, the effect of MSNA on carotid-femoral pulse wave velocity was primarily mediated through BP in older postmenopausal women. All studies mentioned above involved healthy nonobese subjects; therefore, it remains unknown as to whether in obesity, chronic elevation of sympathetic nervous activity contributes to arterial stiffness. Data from a multicenter trial 52 revealed that after 6 months of renal sympathetic denervation, aortic distensibility was restored in patients with resistant hypertension and that these improvements appeared to be unrelated to observed BP changes, suggesting a direct effect of sympathetic renal denervation on the vascular remodeling. Likewise, Brandt et al 53 indicated that sympathetic renal denervation significantly improved arterial stiffness and central hemodynamics.
Strategies to Reduce Cardiovascular Risk in Obesity and Their Effects on Sympathetic Activity Lifestyle Interventions
Weight reduction induced by changes in lifestyle can reverse many related metabolic and hemodynamic abnormalities and is, in general, the best approach to decrease BP. In addition to improving the lipid profile, glucose metabolism, and insulin sensitivity, diet-induced weight reduction is associated with improved cardiac structure and function 40 and is recommended in the treatment of sleep apnea. 54 A meta-analysis of randomized controlled trials investigating the effects of dietary pattern on BP 55 revealed that healthy dietary patterns such as the Dietary Approaches to Stop Hypertension diet, Nordic diet, and Mediterranean diet significantly lowered systolic and diastolic BPs by 4 and 2 mm Hg, respectively. In addition to lowering BP, the Dietary Approaches to Stop Hypertension diet was also been shown to reduce sympathetic activity, as indicated from measures of whole body norepinephrine spillover to plasma and by microneurography recording, and improve baroreflex sensitivity and insulin sensitivity. 56 Dietinduced decreases in SNS activity may be an integral part in improving many of the metabolic and cardiovascular risk factors. The addition of moderate-intensity physical activity does not confer additional benefits on resting SNS activity and metabolic improvement, suggesting that weight loss is most important. 56 Although a successful weight loss program is an essential treatment for obesity-related diseases, it is well known that the majority of individuals do not succeed in weight loss maintenance. Both the large-scale Diabetes Prevention program and the Look Ahead trial demonstrated that the short-term success of lifestyle change in lowering obesity is offset in the long term by rebound weight gain. 57, 58 Masuo et al 59 demonstrated that high sympathetic activity (characterized by high plasma norepinephrine levels) and genetic predisposition may be at play, with individuals carrying the Gly16 allele of the Arg16Gly of the β2-adrenoceptor polymorphism being more likely to be resistant to weight loss and more likely to present rebound weight gain. Straznicky et al 60 observed that subjects' MSNA but not body noradrenaline spillover rebounded after 4 months of weight loss maintenance, with the rebound in MSNA tightly associated with small changes in abdominal fat mass. The stabilization of a low whole-body norepinephrine spillover during stable energy balance may be the key to maintain better cardiovascular risk factors in subjects who are still overweight.
Bariatric Surgery
Bariatric surgery is an established and effective part of the weight loss management of clinically severely obese patients. It is indicated in obese patients with a BMI≥40 kg/m 2 or in individuals with a BMI>35 kg/m 2 in the presence of type 2 diabetes mellitus or other major comorbidities. 61 Bariatric surgery now has an impressive short-term and long-term evidence base for safety and efficacy at inducing weight loss, along with remission and improvement of obesity-related conditions. 62 Interestingly, it has been noted after bariatric surgery that the post-weight loss state conveys benefits that are greater than those predicted by the attained BMI. 63 We recently demonstrated that in patients achieving 10% weight loss after laparoscopic adjustable gastric band surgery, benefits including reduction in MSNA and improvement in BP, baroreflex sensitivity, metabolic profile, and renal function 64 were evident. Similar results were noticed 6 months and 1 year after vertical sleeve gastrectomy where subjects showed, in addition to metabolic and hemodynamic improvements, a substantial decrease in MSNA. 65 The effects of sleeve gastrectomy on sympathetic tone may be mediated, at least in part, by the reduction in the elevated levels of plasma leptin but also by an improvement in baroreflex function. 65 After gastric bypass surgery, it was noticed that the subjects who had surgery had lower levels of MSNA than the obese subjects who have never had surgery. In addition, there was an almost complete absence of sympathetic contribution to resting energy expenditure, suggesting that this may have important consequences for the maintenance of weight loss after gastric bypass. 66 
Pharmacological Weight Loss Agents
The development of safe antiobesity medications has proven to be difficult as new agents have been often plagued by high rates of adverse effects. A meta-analysis reported that medications approved for long-term obesity treatment, when used as an adjunct to lifestyle intervention, lead to greater mean weight loss (3%-9%) and an increased likelihood of achieving clinically meaningful 1-year weight loss relative to placebo. 67 Phentermine is a commonly used weight loss medication in the United States and Australia. Its action seems to be via a central sympathomimetic effect on appetite. Observational data suggest no adverse effect on BP or heart rate. A combination of phentermine and topiramate (Qsymia) is available for weight management in the United States. Studies of this effective combination have found modest reductions in BP and heart rate with weight loss. 68 Orlistat, a lipase inhibitor, has particular benefits on low-density lipoprotein cholesterol and glycemia (10% and 7% reductions) and reduces the risk of developing diabetes mellitus. Observations in a small cohort of patients indicated that orlistat decreased sympathetic nerve traffic by 20% in patients who were obese normotensive and by 26% in those who were obese hypertensive. 69 Lorcaserin, a 5HT2c agonist, provides modest weight loss and has been shown to be noninferior to placebo in a cardiovascular outcomes study performed in high-risk patients. 70 The combination of Naltrexone and Bupropion (Contrave) is approved widely for weight management and generates a small increase in BP and heart rate possibly through the action of bupropion on central sympathetic activity. Overall, there is a poor understanding of the effects of the approved weight loss medications on the SNS.
Antihypertensive Agents
While current hypertension guidelines do not provide specific recommendations for treatment of hypertension in the presence of obesity, inhibitors of the renin-angiotensin system such as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are widely considered as first choice due to their favorable side effect profile, documented cardiorenal protection, and additional beneficial metabolic effects. It is unclear if these effects are mediated through interaction between the renin-angiotensin system and SNS because angiotensin receptor blockers such as losartan and eprosartan were found to exert no effect on MSNA in humans, 71 while treatment with candesartan exerts a sympathoinhibitory effect. 72 Most hypertension guidelines generally recommend calcium channel blockers and diuretics as the appropriate add-on drugs if combination therapy is required. However, while diuretics are useful in counteracting the volume overload frequently evident in obesity hypertension, their adverse metabolic effects and their capacity to further exaggerate the already increased sympathetic drive renders them a suboptimal choice. Given the important role of sympathetic activation in obesity, the use of β-blockers may seem as a plausible antihypertensive option; however, their association with weight gain induced by a blunting of the energy expenditure 73 and other adverse metabolic consequences such as worsening of insulin resistance due to reduced diet-induced thermogenesis, fat oxidation, and physical activity is problamatic in this context. Newer β-blockers such as carvedilol and nebivolol seem to have overcome these problems and have been shown to improve the lipid profile and insulin resistance and not to increase weight. These findings may be of clinical relevance as these antihypertensive drugs could be a valuable aid for subjects with the metabolic syndrome.
Centrally acting sympatholytic agents such as imidazoline I1 agonists, which effectively inhibit sympathetic outflow at the level of the rostral ventrolateral medulla, are not frequently considered in the treatment of hypertension in obesity, yet there is evidence of possible beneficial effects. For instance, in patients with hypertension, moxonidine improved LV mass and capillary blood flow slowed the decline of renal function, improved endothelial function, insulin sensitivity, fasting plasma glucose, low-density lipoprotein cholesterol, and leptin levels. 74 One study also indicated that moxonidine was associated with 2.1-kg weight loss. 75 A study indicated that in nonhypertensive overweight males, the addition of moxonidine to a low-calorie diet, which decreased MSNA, had beneficial effects on glomerular hyperfiltration and liver enzymes 31 ( Figure 4 ). However, whether these beneficial effects significantly influence outcome has not been explored.
Cholesterol-Lowering Drugs
Statins or 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors competitively act on the mevalonate pathway to reduce endogenous production of cholesterol. Large-scale trials have demonstrated that statins reduce cardiovascular morbidity and mortality in high-risk populations and the risk of major vascular events in low-risk populations. 76 It has been acknowledged that a pleiotropic property of statins may include an effect on the autonomic nervous system. Regardless of type and dose, statins reduce sympathetic activity measured by microneurography. 77 Although the central mechanisms of sympathoinhibitory effect of statins is suggested, the relationship between lipid-lowering effects of drugs and their sympathoinhibitory effect remains unclear. Lately, Tokuhisa et al 78 demonstrated that in nonobese patients with heart failure, lipophilic statins (atorvastatin) have a favorable effect on sympathetic nerve activity beyond lowering low-density lipoprotein cholesterol in heart failure patients, but hydrophilic statins (rosuvastatin) do not.
Insulin Sensitizers and Antidiabetic Drugs
Many types of antidiabetic drugs are available to lower blood glucose; however, it is not clear as to whether these drugs affect sympathetic nerve activity. Metformin, the first-line treatment for type 2 diabetes mellitus, may not lead to any change in SNS activity as a 6-week metformin treatment in obese insulin resistant subjects did not change arterial pressure nor MSNA. 79 Pioglitazone, which improves insulin resistance by acting on peroxisome proliferator responsive elements, reduced the composite of allcause mortality, nonfatal myocardial infarction, and stroke in patients with type 2 diabetes mellitus at a high risk of macrovascular events. 80 Given that pioglitazone is able to decrease MSNA in patients with type 2 diabetes mellitus 81 and in those with type 2 diabetes mellitus after a recent myocardial infarction, 82 it is believed that sympathoinhibitory effects of pioglitazone may, at least in part, contribute to the beneficial effects of this drug, although another study indicated that pioglitazone induced only a marginal reduction in MSNA and no effect on whole-body norepinephrine spillover. 83 Glucagon-like peptide 1 (GLP1) is an incretin which acts on pancreas to secrete insulin and centrally to reduce weight. GLP1 analogs such as exenatide and liraglutide are promising new treatment options for patients with type 2 diabetes mellitus and have been associated with modest reduction in body weight and BP but, conversely, have been linked with a small increase in heart rate. 84 Although experimental studies of GLP-1 analogs have reported that the direct effects on BP could possibly involve an interaction with the autonomic nervous system, 84 a small clinical investigation reported that acute GLP-1 increased MSNA. 85 The short-and long-term effects of GLP1 on sympathetic function are unknown.
More recent investigations have highlighted an emerging role for inhibition of the SGLT-2 (sodium-glucose cotransporter 2). Empagliflozin has been shown to not only improve glucose control but also to result in BP lowering and perhaps more importantly to reduce cardiovascular events in patients with diabetes mellitus. 86 While inhibition of central sympathetic outflow associated with SGLT-2 treatment is not evident after 4 days, 87 whether a longer term treatment may have an effect is unknown.
Conclusions and Perspectives
The current prevalence and projected figures of obesity and its impact on health and the health system are alarming. While implementation of lifestyle changes is the core treatment for overweight patients, the limited success in achieving and sustaining appropriate weight loss means that interventions and strategies that optimize weight loss but also limit obesity-related cardiometabolic disease development and progression are urgently needed. It is likely that obese patients will require multiple approaches to reduce weight and decrease their cardiovascular and metabolic complications and cardiovascular risk. Moreover, given that obesity-associated organ damage is evident even with modest weight gain in the absence of demonstrable metabolic abnormalities, new treatments need to be developed and implemented early. Based on the data discussed above, the improvements in metabolic and cardiovascular risk factors associated with weight loss induced by either lifestyle changes or surgery are tightly linked with a reduction in SNS activity. Whether therapeutically targeting obesityrelated SNS activity is a viable strategy to reduce the burden of obesity-related illness remains unknown. Undoubtedly, a reduction in the sympathetic tone through targeted therapy for the control of BP or indirectly through the control of the metabolic profile have demonstrable positive effects. The finding that adding moxonidine to a low-calorie diet had further beneficial effects in a small group of young overweight males is promising 31 but needs to be confirmed in larger, longitudinal trials. Further research is clearly needed to establish whether sympathetic inhibition may be considered a priority in the treatment of cardiovascular and metabolic consequences of obesity. 
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